• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中性粒细胞与淋巴细胞比值和血清糖类抗原19-9联合检测对胰头癌患者的预后影响

Prognostic impact of the combination of the neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 in patients with pancreas head cancer.

作者信息

Kim Wan-Joon, Lim Tae-Wan, Park Pyoung-Jae, Choi Sae-Byeol, Kim Wan-Bae

机构信息

Division of Hepatobiliary Pancreas Surgery, Department of Surgery, Korea University Guro Hospital, Korea University Medical College, Seoul, Korea.

Division of Transplantation Vascular Surgery, Department of Surgery, Korea University Guro Hospital, Korea University Medical College, Seoul, Korea.

出版信息

ANZ J Surg. 2019 Jul;89(7-8):E302-E307. doi: 10.1111/ans.15029. Epub 2019 Mar 20.

DOI:10.1111/ans.15029
PMID:30895709
Abstract

BACKGROUND

This study aimed to evaluate the clinical value of the combination of a traditional prognostic factor with a systemic inflammation-based prognostic factor in patients undergoing curative resection for pancreas head cancer diagnosed as pancreatic ductal adenocarcinoma.

METHODS

From January 2005 to December 2015, 198 patients were enrolled. Various clinicopathological factors potentially associated with survival and recurrence were evaluated in this study.

RESULTS

The selected cut-off values for the test prognostic factors with sufficient sensitivity and specificity were 2.8 for the neutrophil-to-lymphocyte ratio (NLR) and 70 U/mL for serum carbohydrate antigen 19-9 (CA19-9). Kaplan-Meier survival analysis demonstrated that the 5-year survival rate in patients with a high NLR and CA19-9 was 21.8% compared with 79.8% for patients with a low NLR and CA19-9. The 5-year disease-free survival rate in patients with a high NLR and CA19-9 was 0% compared with 33.9% for patients with a low NLR and CA19-9. Patients with high NLRs and high CA19-9 were more likely to have an early recurrence and multiple relapse patterns.

CONCLUSION

Preoperative NLR and serum CA19-9 offer significant prognostic information for survival following curative resection of pancreas head cancer diagnosed as pancreatic ductal adenocarcinoma.

摘要

背景

本研究旨在评估传统预后因素与基于全身炎症的预后因素相结合,在接受根治性切除的胰腺导管腺癌诊断为胰头癌患者中的临床价值。

方法

2005年1月至2015年12月,共纳入198例患者。本研究评估了各种可能与生存和复发相关的临床病理因素。

结果

具有足够敏感性和特异性的测试预后因素的选定临界值为中性粒细胞与淋巴细胞比值(NLR)为2.8,血清糖类抗原19-9(CA19-9)为70 U/mL。Kaplan-Meier生存分析表明,高NLR和CA19-9患者的5年生存率为21.8%,而低NLR和CA19-9患者为79.8%。高NLR和CA19-9患者的5年无病生存率为0%,而低NLR和CA19-9患者为33.9%。高NLR和高CA19-9的患者更有可能早期复发和出现多发复发模式。

结论

术前NLR和血清CA19-9为诊断为胰腺导管腺癌的胰头癌根治性切除后的生存提供了重要的预后信息。

相似文献

1
Prognostic impact of the combination of the neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 in patients with pancreas head cancer.中性粒细胞与淋巴细胞比值和血清糖类抗原19-9联合检测对胰头癌患者的预后影响
ANZ J Surg. 2019 Jul;89(7-8):E302-E307. doi: 10.1111/ans.15029. Epub 2019 Mar 20.
2
Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.术前中性粒细胞与淋巴细胞比值(NLR)和糖类抗原19-9(CA19-9)对胰腺癌的预后影响
Pancreatology. 2016 May-Jun;16(3):434-40. doi: 10.1016/j.pan.2015.10.006. Epub 2015 Nov 10.
3
The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.中性粒细胞与淋巴细胞比值和血清糖类抗原19-9水平联合作为复发性胰腺癌患者的预后指标
Anticancer Res. 2018 Sep;38(9):5497-5503. doi: 10.21873/anticanres.12883.
4
Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients.联合预处理血清CA19-9和中性粒细胞与淋巴细胞比值作为转移性胰腺癌患者的潜在预后因素。
Medicine (Baltimore). 2018 Jan;97(4):e9707. doi: 10.1097/MD.0000000000009707.
5
The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases.中性粒细胞与淋巴细胞比值在预测胰腺疾病患者胰腺导管腺癌中的诊断作用。
Int J Clin Oncol. 2016 Oct;21(5):940-945. doi: 10.1007/s10147-016-0975-z. Epub 2016 Mar 29.
6
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.术前 CEA 和 CA 19-9 是可切除性胰腺导管腺癌患者生存的预后标志物——一项回顾性肿瘤标志物预后研究。
Int J Surg. 2013;11(10):1067-72. doi: 10.1016/j.ijsu.2013.10.005. Epub 2013 Oct 23.
7
Prognostic value of neutrophil to lymphocyte ratio in patients with advanced pancreatic ductal adenocarcinoma treated with systemic chemotherapy.中性粒细胞与淋巴细胞比值对接受系统化疗的晚期胰腺导管腺癌患者的预后价值。
Ann Med. 2024 Dec;56(1):2398725. doi: 10.1080/07853890.2024.2398725. Epub 2024 Sep 2.
8
Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer.术前血小板与淋巴细胞比值和血清糖类抗原 19-9 联合水平作为可切除胰腺癌患者的预后因素。
Hepatobiliary Pancreat Dis Int. 2019 Jun;18(3):278-284. doi: 10.1016/j.hbpd.2019.03.010. Epub 2019 Apr 5.
9
Prognostic significance of neutrophil-lymphocyte ratio and carbohydrate antigen 19-9 in patients with gallbladder carcinoma.中性粒细胞与淋巴细胞比值及糖类抗原19-9在胆囊癌患者中的预后意义
Medicine (Baltimore). 2019 Feb;98(8):e14550. doi: 10.1097/MD.0000000000014550.
10
Prognostic value of the neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 in estimating survival in patients with metastatic pancreatic cancer.中性粒细胞与淋巴细胞比值及糖类抗原19-9在评估转移性胰腺癌患者生存率中的预后价值
J Cancer Res Ther. 2020 Jul-Sep;16(4):909-916. doi: 10.4103/jcrt.JCRT_366_19.

引用本文的文献

1
The Role of Resolvin D1 in the Differential Diagnosis of Pancreatic Ductal Adenocarcinoma and Acute Pancreatitis: A Case-Control Study.消退素D1在胰腺导管腺癌与急性胰腺炎鉴别诊断中的作用:一项病例对照研究。
Medicina (Kaunas). 2025 Jan 21;61(2):168. doi: 10.3390/medicina61020168.
2
Combination of neutrophil-to-lymphocyte ratio and serum CA 19-9 as a prognostic factor in pancreatic cancer.中性粒细胞与淋巴细胞比值联合血清CA 19-9作为胰腺癌预后因素的研究
J Gastrointest Oncol. 2024 Aug 31;15(4):1805-1819. doi: 10.21037/jgo-23-893. Epub 2024 Aug 22.
3
Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma.
基于生物标志物的评分系统预测可切除胰腺导管腺癌早期复发的研究进展。
Ann Surg Oncol. 2022 Feb;29(2):1281-1293. doi: 10.1245/s10434-021-10866-6. Epub 2021 Oct 4.
4
Does Preoperative Serum Neutrophil to Lymphocyte Ratio (NLR), Platelet to Lymphocyte Ratio (PLR), and Lymphocyte to Monocyte Ratio (LMR) Predict Prognosis Following Radical Surgery for Pancreatic Adenocarcinomas? Results of a Retrospective Study.术前中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)和淋巴细胞与单核细胞比值(LMR)是否能预测胰腺腺癌根治性手术后的预后?一项回顾性研究的结果。
J Gastrointest Cancer. 2022 Sep;53(3):641-648. doi: 10.1007/s12029-021-00683-1. Epub 2021 Aug 18.
5
C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients.C反应蛋白与中性粒细胞/淋巴细胞比值:胰腺癌患者总生存期翻倍预测的预后指标
J Clin Med. 2019 Oct 25;8(11):1791. doi: 10.3390/jcm8111791.